Literature DB >> 1510421

Metabolic disposition of DQ-2556, a new cephalosporin, in rats, rabbits, dogs, and monkeys.

K Matsubayashi1, S Shintani, M Yoshioka, H Tachizawa.   

Abstract

The metabolic disposition of DQ-2556 was studied in rats, rabbits, dogs, and monkeys after an intravenous administration of 20 mg of 14C-labeled drug per kg of body weight. The serum data were analyzed by the two-compartment open model. The mean half-lives for the drug in serum at excretion phase were 18.1, 54.4, 21.8, and 63.6 min in rats, rabbits, dogs, and monkeys, respectively. The volume of distribution and total body clearance ranged from 0.18 to 0.30 liter/kg and 0.065 to 0.45 liter/h/kg, respectively. This compound was distributed to the tissues rapidly and well, especially to the kidney, trachea, liver, thyroid, skin, and lung. Tissue concentrations declined rapidly in a few hours and then very slowly. However, no accumulation was observed in any tissues. The results of a protein-binding study by ultracentrifugation indicated that DQ-2556 was 20 to 30% bound to serum proteins in animals and its affinity was low. Almost 90% of the administered radioactivity was excreted into urine in all species. Biliary excretion in rats was 3.1% of the dose. Nearly 70% of the dose or more was excreted into urine as unchanged drug, and the amounts of urinary metabolites were small except in rabbits, in which substantial amounts of polar metabolites were detected.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510421      PMCID: PMC188793          DOI: 10.1128/AAC.36.5.966

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Synthesis and biological evaluation of a series of parenteral 3'-quaternary ammonium cephalosporins.

Authors:  R F Brown; M D Kinnick; J M Morin; R T Vasileff; F T Counter; E O Davidson; P W Ensminger; J A Eudaly; J S Kasher; A S Katner
Journal:  J Med Chem       Date:  1990-08       Impact factor: 7.446

2.  Simple method for determination of the cephalosporin DQ-2556 in biological fluids by high-performance liquid chromatography.

Authors:  K Matsubayashi; M Yoshioka; H Tachizawa
Journal:  J Chromatogr       Date:  1990-08-31

3.  The blood binding of cefotiam and cyclohexanol, metabolites of the prodrug cefotiam hexetil, in-vitro.

Authors:  V Querol-Ferrer; R Zini; J P Tillement
Journal:  J Pharm Pharmacol       Date:  1991-12       Impact factor: 3.765

4.  Synthesis and antimicrobial activity of cephalosporins with a 1-pyridinium substituent carrying a 5-membered heterocycle at the C-3 position.

Authors:  A Ejima; T Hayano; T Ebata; T Nagahara; H Koda; H Tagawa; M Furukawa
Journal:  J Antibiot (Tokyo)       Date:  1987-01       Impact factor: 2.649

5.  In-vitro antibacterial activity of DQ-2556 and its stability to various beta-lactamases.

Authors:  T Fujimoto; M Watanabe; M Inoue; S Mitsuhashi
Journal:  J Antimicrob Chemother       Date:  1990-09       Impact factor: 5.790

6.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

7.  Effect of altered plasma protein binding on apparent volume of distribution.

Authors:  S Oie; T N Tozer
Journal:  J Pharm Sci       Date:  1979-09       Impact factor: 3.534

8.  Effect of DQ-2556, a new cephalosporin, on organic ion transport in renal plasma membrane vesicles from the dog, rabbit and rat.

Authors:  P P Sokol
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

9.  In vitro activity of DQ-2556, a new cephalosporin.

Authors:  T Fujimoto; T Otani; R Nakajima; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

10.  Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy.

Authors:  A Tsuji; H Sato; I Tamai; H Adachi; T Nishihara; M Ishiguro; N Ohnuma; T Noguchi
Journal:  Drug Metab Dispos       Date:  1990 Mar-Apr       Impact factor: 3.922

View more
  1 in total

1.  In vitro and in vivo activities of DQ-2556 and its mode of action.

Authors:  M Tanaka; M Otsuki; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.